Fairvalue-Calculator Fairvalue-Calculator
EN DE

Atea Pharmaceuticals, Inc (AVIR) Fair Value & Analysis

Healthcare · US · Market cap $347M

Price$4.48
Fair Value$3.39
Upside-24.3%
Quality95/100
Evidence: Low Range $2.24 – $4.24

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Atea Pharmaceuticals, Inc (AVIR) currently trades at $4.48, while our model-based Fair Value estimate is $3.39 — implying the stock looks roughly 24.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Atea Pharmaceuticals, Inc (AVIR) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.39 versus a price of $4.48 — about −24% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AVIR?
Our 21-model fair value for Atea Pharmaceuticals, Inc is $3.39 (as of Jun 25, 2026), built from audited fundamentals. The current price is $4.48.
What is the quality score of AVIR?
Atea Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.